Commercialisation Models for PDT's

Commercialisation models for PDTs are still evolving. It’s not always a straightforward process of checking a box for approval or determining whether a PDT should be over-the-counter or prescription-based. 

Pharma companies play an important role in distributing PDTs due to their established relationships with payers and providers. Recent regulatory guidance has further enhanced their role by allowing the inclusion of “Software as a Medical Device” in drug labels. This means that pharma companies have an increased opportunity to contribute to the distribution of PDTs. Alternate commercialisation channels, such as digital health platforms offering pharma medication distribution, are emerging. 

Ultimately, commercialisation models need to take into account existing and emerging distribution and prescription pathways.  Join this meeting to discuss how to leverage existing synergies to drive commercialisation models for PDTs:

• What metrics and outcome measures should be used to assess the effectiveness and value of PDTs to inform commercialisation strategies and decision-making? 
• What innovative pricing and reimbursement models can be explored to ensure the long-term sustainability of PDTs, while also incentivising continued research and development in the field? 
• How can commercialisation models for PDTs effectively balance the need for patient access and affordability with the financial sustainability of DTx companies?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.